title: The inhibitory effect of (111)In-DTPA(0)-octreotide on intrahepatic tumor growth after partial hepatectomy.
abstract: The aim of this animal study was to evaluate whether peptide receptor radionuclide therapy with (111)In-diethylenetriaminepentaacetic acid (DTPA)(0)-octreotide was able to reduce tumor growth even under tumor growth-stimulating conditions induced by partial hepatectomy (PHx).
  
  
  METHODS
  Rats underwent 70% PHx or sham operation. The development of hepatic metastases was determined 21 d after direct injection of somatostatin receptor (SS-R)-positive or SS-R-negative tumor cells into the portal vein. Groups of 8 or 9 animals that underwent PHx or sham operation were treated with octreotide 50 micro g/kg subcutaneously twice daily or with 370 MBq (111)In-DTPA(0)-octreotide intravenously on days 1 and 8. Both treatments were compared with control treatment. Forty non-tumor-bearing rats were used to determine the influence of (111)In-DTPA(0)-octreotide therapy on liver regeneration after PHx.
  
  
  RESULTS
  PHx induced an increase in tumor growth in all experiments (P < 0.01). Octreotide treatment did not influence tumor growth after PHx or sham operation. (111)In-DTPA(0)-octreotide could effectively reduce tumor growth in the liver of SS-R-positive tumors also under conditions of increased tumor growth as generated by PHx (P < 0.01). (111)In-DTPA(0)-octreotide was also effective on SS-R-negative tumors after PHx (P = 0.01) but not after sham operation. Furthermore, (111)In-DTPA(0)-octreotide therapy did not influence liver regeneration or liver function after PHx.
  
  
  CONCLUSIONS
  Peptide receptor radionuclide therapy with (111)In-DTPA(0)-octreotide is effective in SS-R-positive tumors. During liver regeneration, the growth of SS-R-negative tumors is also reduced. This effect is not induced by impairment of liver regeneration or liver function. Radionuclide therapy could therefore be a promising treatment modality for patients with symptomatic liver metastases of neuroendocrine tumors in combination with liver resection.
authors.affiliation: Department of Surgery, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.
authors.forename: Gerrit D
authors.initials: GD
authors.lastname: Slooter
authors.forename: Arend G J
authors.initials: AG
authors.lastname: Aalbers
authors.forename: Wouter A P
authors.initials: WA
authors.lastname: Breeman
authors.forename: Coen A
authors.initials: CA
authors.lastname: Hiemstra
authors.forename: Richard L
authors.initials: RL
authors.lastname: Marquet
authors.forename: Eric P
authors.initials: EP
authors.lastname: Krenning
authors.forename: Casper H J
authors.initials: CH
authors.lastname: van Eijck
mesh_terms: D000818:Animals; D006498:Hepatectomy; D007205:Indium Radioisotopes / Q000627:therapeutic use*; D008114:Liver Neoplasms, Experimental / Q000737:chemistry / Q000532:radiotherapy* / Q000601:surgery; D008115:Liver Regeneration; D008297:Male; D015282:Octreotide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004369:Pentetic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D051381:Rats; D011917:Rats, Inbred Lew; D017481:Receptors, Somatostatin / Q000032:analysis
chemical_list: D007205:Indium Radioisotopes; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin; D004369:Pentetic Acid; D015282:Octreotide